The Patent Finder
IN

Incyte Corporation

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

449 patents currently held

86 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
40
Ending by 2030
Dec 2026
Next term end
232
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 437 later US patents, top 1% of utility patents granted in 2009 in our data. Protection runs to 2027.
Ends Dec 2027 · High confidence
Also notable
Cited by 103 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2034.
Ends May 2034 · High confidence
Also notable
Cited by 205 later US patents, top 5% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Ends Aug 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 28 to 30, 2026 · next Nov 28
  • 7 fees due Dec 4 to 27, 2026 · next Dec 4
  • 5 fees due Jan 2 to 30, 2027 · next Jan 2
  • 9 fees due Feb 1 to 28, 2027 · next Feb 1
  • 5 fees due Mar 12 to 26, 2027 · next Mar 12
  • 14 fees due Apr 1 to 24, 2027 · next Apr 1
  • 8 fees due May 5 to 21, 2027 · next May 5
  • 13 fees due Jun 1 to 30, 2027 · next Jun 1
  • 8 fees due Jul 9 to 30, 2027 · next Jul 9
  • 10 fees due Aug 6 to 27, 2027 · next Aug 6
  • 12 fees due Sep 5 to 26, 2027 · next Sep 5
  • 14 fees due Oct 7 to 28, 2027 · next Oct 7
  • 5 fees due Nov 5 to 14, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 232 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 9,662,335Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,814,722Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,974,790Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,398,699HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 10,639,310Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,331,320HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 11,744,832HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
In force
 · High confidence
In forceHigh confidence
US 7,910,108Sheddase Inhibitors Combined with CD30-Binding Immunotherapeutics for the Treatment of CD30 Positive Diseases
In force
 · High confidence
In forceHigh confidence
US 7,511,050Purinone Derivatives as HM74A Agonists
In force
 · High confidence
In forceHigh confidence
US 7,902,205Purinone Derivatives as HM74A Agonists
In force
 · High confidence
In forceHigh confidence
10 of 449 patents shown.
Pro members see all 449.
Pro members: see all 449 patents
Also on record, not counted in the 449: 86 patents in force now held by others · 119 patents ended · 189 applications pending · 438 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited